MeVis Medical Solutions AG

MeVis Medical Solutions AG

M3V.DE
MeVis Medical Solutions AGDE flagDeutsche Börse
23.20
EUR
- -
- -
42.22MMarket Cap
MeVis Medical Solutions AG
M3V.DE
(Deutsche Börse)

Recent

price

23.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.16
8.37
7.95
7.75
7.42
7.6
8.94
10.19
9.77
9.93
9.41
8.91
10.31
9.53
9.33
- -
9.91
Revenue per Share
0.23
-4.89
-2.38
1.26
2.14
2.16
3.76
3.09
4.19
4.43
3.13
2.5
4.28
2.7
2.51
- -
4.43
Basic EPS, GAAP
0.02
1.04
2.74
2.96
4.23
2.59
3.61
3.9
2.71
3.48
1.53
4.99
2.6
3.17
1.56
- -
3.48
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.04
- -
5.15
0.89
0.86
3.13
2.5
4.28
2.7
- -
- -
Dividend per Share
3.98
-0.8
-3.02
-1.61
11.25
13.43
14.03
13.63
3.49
3.49
3.49
3.49
3.49
3.49
3.49
- -
3.49
Book Value per Share
3.24
1.63
1.05
4.11
6.26
8.5
11.1
11.42
9.74
9.78
9.79
9.79
9.79
9.79
9.79
- -
9.76
Tangible Book Value per Share
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
- -
2
Basic Weighted Avg Shares
14
14
14
13
13
13
16
19
18
18
17
16
19
17
17
16
18
Sales/Revenue/Turnover
11.77
-37.97
7.82
22.56
34.42
30.02
30.06
43.32
40.56
39.51
36.02
31
34.49
28.28
23.58
14.58
39.51
Operating Margin (%)
3
9
6
3
2
2
2
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-8
-4
2
4
4
7
6
8
8
6
5
8
5
5
3
8
Net Income, GAAP
65.92
- -
- -
8.27
6.76
24.9
- -
21.57
1.15
1.04
1.56
1.84
1.11
2.27
2.7
3.45
1.04
Effective Tax Rate (%)
2.87
-58.42
-29.92
16.21
28.8
28.36
42.06
30.32
42.86
44.66
33.3
28.04
41.52
28.37
26.87
19.71
44.66
Profit Margin (%)
10
6
5
7
11
15
17
17
4
4
4
4
5
5
3
3
4
Working Capital
7
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
33
25
21
23
26
30
34
33
18
18
18
18
18
18
18
18
18
Total Equity
1.26
- -
- -
11.2
15.74
10.03
- -
15.27
22.72
37.64
33.87
27.51
35.66
26.68
21.68
12.6
37.64
Return on Invested Capital (%)
4.41
- -
- -
-143.76
43.78
17.57
- -
17.75
36.23
112.71
89.87
71.64
122.54
78.01
72.01
49.79
112.58
Return on Capital (%)
6.15
- -
- -
- -
- -
17.47
27.92
22.52
48.89
126.91
89.69
71.48
122.48
77.36
71.71
49.78
126.91
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'19
Jun'19
Sep'19
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
49
46
47

Working Capital

FRC

in mil. unless spec.
Mar'19
Jun'19
Sep'19
Total Current Assets
8
10
7
Cash, Cash Equivalents & STI
2
3
3
Accounts Receivable, Net
3
3
2
Inventories
- -
- -
- -
Total Current Liabilities
3
4
4
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
17.74%
36.15%
31.44%
Net Income, GAAP
5.33%
-4.73%
-30.58%
Sales/Revenue/Turnover
2.57%
-0.94%
-5.37%
Total Cash Common Dividend
- -
54%
-7.29%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
17
2024
- -
- -
- -
- -
17
2025
- -
- -
- -
- -
16

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.7
2024
- -
- -
- -
- -
2.51
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4.28
2024
- -
- -
- -
- -
2.7
2025
- -
- -
- -
- -
- -
Business
MeVis Medical Solutions AG (M3V.DE) develops and markets software solutions for medical imaging analysis and visualization, primarily focused on diagnostic support in radiology and oncology. The company offers advanced image processing tools including MeVisLab, a modular platform for creating customized medical image processing applications; Riverain Medical's ClearRead Detect and ClearRead Compare for chest CT and X-ray analysis to aid in lung nodule and lesion detection; Fraunhofer MEVIS research software for liver and lung applications; and services such as customized software development, regulatory validation, and clinical workflow integration. These products serve healthcare providers, medical device manufacturers, and research institutions worldwide, with operations spanning Europe, North America, and Asia; MeVis Medical Solutions AG was founded in 1995 and is headquartered in Bremen, Germany, as a subsidiary of Fraunhofer-Gesellschaft. In recent developments, the company completed the acquisition of Riverain Medical in 2023, expanding its AI-powered chest imaging portfolio with FDA-cleared technologies for early lung disease detection, followed by CE marking approvals in Europe for ClearRead products in 2024. MeVis continues to advance its oncology-focused software through partnerships with leading radiology systems providers and participation in Fraunhofer research initiatives on multimodal imaging. No major funding rounds, name changes, or operational reorganizations have been reported in the last two years, with strategic emphasis on integrating acquired technologies into global sales channels and enhancing AI capabilities for precision diagnostics.